Earlier this year, Exscientia announced what was said to be the first AI-designed immuno-oncology drug to enter clinical trials. Lu Rahman talks to CEO Andrew Hopkins about the company’s work and use of AI in drug discovery. LR:  How AI has been used in this process and what benefits has it created? AH: AI was […]